Literature DB >> 35157049

Bias and Pancreatic Cancer Reporting.

Howard S Hochster1, H Richard Alexander1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35157049      PMCID： PMC9086751          DOI： 10.1093/jnci/djac020

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   11.816


× No keyword cloud information.
  6 in total

1.  Impact of centralization of pancreatic cancer surgery on resection rates and survival.

Authors:  G A Gooiker; V E P P Lemmens; M G Besselink; O R Busch; B A Bonsing; I Q Molenaar; R A E M Tollenaar; I H J T de Hingh; M W J M Wouters
Journal:  Br J Surg       Date:  2014-05-20       Impact factor: 6.939

2.  Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.

Authors:  Janet E Murphy; Jennifer Y Wo; David P Ryan; Wenqing Jiang; Beow Y Yeap; Lorraine C Drapek; Lawrence S Blaszkowsky; Eunice L Kwak; Jill N Allen; Jeffrey W Clark; Jason E Faris; Andrew X Zhu; Lipika Goyal; Keith D Lillemoe; Thomas F DeLaney; Carlos Fernández-Del Castillo; Cristina R Ferrone; Theodore S Hong
Journal:  JAMA Oncol       Date:  2018-07-01       Impact factor: 31.777

3.  Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.

Authors:  Quisette P Janssen; Stefan Buettner; Mustafa Suker; Berend R Beumer; Pietro Addeo; Philippe Bachellier; Nathan Bahary; Tanios Bekaii-Saab; Maria A Bali; Marc G Besselink; Brian A Boone; Ian Chau; Stephen Clarke; Mary Dillhoff; Bassel F El-Rayes; Jessica M Frakes; Derek Grose; Peter J Hosein; Nigel B Jamieson; Ammar A Javed; Khurum Khan; Kyu-Pyo Kim; Song Cheol Kim; Sunhee S Kim; Andrew H Ko; Jill Lacy; Georgios A Margonis; Martin D McCarter; Colin J McKay; Eric A Mellon; Sing Yu Moorcraft; Ken-Ichi Okada; Alessandro Paniccia; Parag J Parikh; Niek A Peters; Hans Rabl; Jaswinder Samra; Christoph Tinchon; Geertjan van Tienhoven; Eran van Veldhuisen; Andrea Wang-Gillam; Matthew J Weiss; Johanna W Wilmink; Hiroki Yamaue; Marjolein Y V Homs; Casper H J van Eijck; Matthew H G Katz; Bas Groot Koerkamp
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

4.  Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Authors:  Cristina R Ferrone; Giovanni Marchegiani; Theodore S Hong; David P Ryan; Vikram Deshpande; Erin I McDonnell; Francesco Sabbatino; Daniela Dias Santos; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Jason E Faris; Lipika Goyal; Eunice L Kwak; Janet E Murphy; David T Ting; Jennifer Y Wo; Andrew X Zhu; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-del Castillo
Journal:  Ann Surg       Date:  2015-01       Impact factor: 12.969

5.  Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer.

Authors:  Marsha Reyngold; Eileen M O'Reilly; Anna M Varghese; Megan Fiasconaro; Melissa Zinovoy; Paul B Romesser; Abraham Wu; Carla Hajj; John J Cuaron; Richard Tuli; Lara Hilal; Danny Khalil; Wungki Park; Ellen D Yorke; Zhigang Zhang; Kenneth H Yu; Christopher H Crane
Journal:  JAMA Oncol       Date:  2021-05-01       Impact factor: 31.777

6.  FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.

Authors:  Quisette P Janssen; Jacob L van Dam; Deesje Doppenberg; Laura R Prakash; Casper H J van Eijck; William R Jarnagin; Eileen M O' Reilly; Alessandro Paniccia; Marc G Besselink; Matthew H G Katz; Ching-Wei D Tzeng; Alice C Wei; Amer H Zureikat; Bas Groot Koerkamp
Journal:  J Natl Cancer Inst       Date:  2022-05-09       Impact factor: 11.816
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.